IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In r	re applic	ation of:	Ingold et al.									
Intl. Serial No.:			PCT/US03/05723 Group Art Unit:									
Intl. File Date:			February 25, 2003	Examiner:	To Be Assigned							
For:			Process for Preparation of Chemical Compounds									
P.C	Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450											
			INFORMATION D	ISCLOSURE STATI	EMENT							
Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97												
	 [X] Copies of the references are enclosed: reference #2 [] Copies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) [X] A copy of the International Search Report which issued on International Application No. PCT/US03/05723 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau. 											
A.	[X]	filing d applica	ate of the above application	or date of entry into the n	being filed within three months of the ational stage of an international on the merits, whichever event							
	OR []	of a fir	formation Disclosure Stat st office action after the fi 1.114 (37 C.F.R. 1.97(b)(4	ling of a Request For Co	h is being filed before the mailing ntinued Examination under 37							
В.	[]	filing date of an internation event occur (1) a f	f the above application or	the date of entry into the namailing date of the first O ling date of either:	ng filed after three months of the ational stage as set forth in § 1.491 of ffice Action on the merits, whichever							
	[]	Applicant h	ereby certifies that each iter	m of information contained n from a foreign patent off	l in this Information Disclosure ice in a counterpart foreign							
	[]		cts the option to pay the featement under § 1.97(c) (\$		p) for submission of an Information							
C.	[]	The Informa	ation Disclosure Statement statement statement statement §	transmitted herewith is bein 1.311, whichever occurs f	ng filed after a final action under § irst, but before the payment of the							

issue fee. Also enclosed is a copy of the International Search Report which Issued on International

In accordance with the requirements of 37 CFR 1.97(d):

Publication No.

PU4722USW



- Applicant hereby certifies that each item of information contained in this Information Disclosure [] Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure [] Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

Robert H. Brink

Registration No. 36,094

Date: 23 August 2004 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-3323 Facsimile: (919) 483-7988

10/505337001

FORM PTO		DISCLOSURE ST	ATEMENT	ATTORNEY DOCKET NO. PU4722USW		SERIAL NO. PCT/US03/05723							
INTORMA	11011	DISCEOSCRESI			APPLICANIOS NECE OPCT/PTO 23 AUG								
					FILING DATE:	1	GROUP AUG ZUU						
February 25, 2003													
U.S. PATENT DOCUMENTS Filing Date													
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	If Appropriate					
	<u> </u>	ļ		ļ		ļ		ļ					
<u> </u>								!					
				+			 	 					
	ļ				<u> </u>	<u> </u>							
	-							<u> </u>					
-				+			*	 					
	L	1	C	ontinue on p	nage	L		1					
-					DOCUMENTS								
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No					
	1	WO 01/00603	Jan. 4, 2001	WIPO									
	2	WO 02/062774	Aug. 15, 2002	WIPO									
		<u> </u>											
					-	ļ							
		 				<u> </u>	<u> </u>						
					<u>.</u> .	ļ		<u></u>					
			<u> </u>	ontinue on p	12Ge	<u>I</u>	<u> </u>	<u>. </u>					
	_	OTHER DOCUM				age Numbe	er. Etc.)						
	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Bebbington, D., et al. "3,5-Disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone: potent inhibitors of lipid peroxidation and cell toxicity." Journal of Medicinal Chemistry, vol. 43, no. 15,												
	4	July 27, 2000, pg. 2780. Sato, R., et al. "Efficient synthesis and biological properties of new benzopentathiepins." Heterocycles, vol.											
	5	41, no. 5, May 1, 1995, pgs 893-896. Tercio, J., et al. "Synthesis of 2,2-dimethyl-2H-thiochromenes, the sulfur analogs of precocenes." Synthesis,											
	6	no. 2, February 1987, pgs. 149-153. Engman, L., et al. "A general procedure for the synthesis of methylthiomethylseleno- and methylluro-											
		substituted aromatic compounds." Journal of Organometallic Chemistry, vol. 296, no. 3, December 3, 1985, pgs. 357-366.											
	7	Malmstrom, J., et al. "Novel antioxidants: unexpected rearrangements in the radical cyclization approach to 2,3-dihydrobenzo'b!thiophene-5-ol derivatives." Journal of Organic Chemistry, vol. 63, no. 10, May 15,											
<u></u>	8	1998, pgs 3318-3323. Gauthier, J.Y., et al. "A remarkably simple conversion of nitriles to thioamides." Phosphorus, Sulfur and Silicon and the Related Elements, vol. 95/95, no. ¼, 1994, pgs 325-326.											
		Silicon and the K	erated Elements,	voi. 93/93, i	110. 74, 1994, pgs 323-32	20.							
	 												
													
			C	ontinue on	page	I DAME OF	a lainean						
EXAMINER DATE CONSIDERED													
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.													